Morgan Stanley Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $145
Morgan Stanley Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $145
Morgan Stanley Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $145
HSBC Initiates BioNTech(BNTX.US) With Buy Rating, Announces Target Price $136
BioNTech Is Maintained at Buy by HSBC
Morgan Stanley Upgrades BioNTech(BNTX.US) to Buy Rating, Raises Target Price to $145
BioNTech Analyst Ratings
H.C. Wainwright Maintains BioNTech(BNTX.US) With Buy Rating, Raises Target Price to $150
Deutsche Bank Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $150
BioNTech SE (BNTX) Gets a Buy From Deutsche Bank
UBS Maintains BioNTech(BNTX.US) With Hold Rating, Maintains Target Price $131
TD Cowen Reaffirms Their Hold Rating on BioNTech SE (BNTX)
BioNTech Analyst Ratings
Morgan Stanley Upgrades BioNTech to Overweight From Equalweight, Boosts Price Target to $145 From $93
BioNTech SE (BNTX) Receives a Hold From Morgan Stanley
BioNTech Analyst Ratings
Deutsche Bank Maintains BioNTech(BNTX.US) With Buy Rating, Raises Target Price to $150
UBS Maintains BioNTech(BNTX.US) With Hold Rating, Raises Target Price to $131
UBS Keeps Their Hold Rating on BioNTech SE (BNTX)
BioNTech Price Target Raised to $150.00/Share From $96.00 by Jefferies